Abstract:Interleukin 10 receptor (IL10R)-deficient mice develop spontaneous colitis and, similarly, patients with loss-of-function mutations in IL10R develop severe infant-onset inflammatory bowel disease. Loss of IL10R signaling in mouse and human macrophages is associated with increased production of interleukin 1β. We demonstrated that innate immune production of IL1β mediates colitis in IL10R-deficient mice. Transfer of Il1r1-/- CD4+ T cells into Rag1-/-/Il10rb-/- mice reduced the severity of their colitis (compared to mice that received CD4+ T cells that express IL1R), accompanied by decreased production of interferon gamma, tumor necrosis factor-α, and IL17A. In macrophages from mice without disruption of IL10R signaling or from healthy humans (controls), incubation with IL10 reduced canonical activation of the inflammasome and production of IL1β through transcriptional and post-translational regulation of NLRP3. Lipopolysaccharide and adenosine triphosphate stimulation of macrophages from Il10rb-/- mice or IL10R-deficient patients resulted in increased production of IL1β. Moreover, in human IL10R-deficient macrophages, lipopolysaccharide stimulation alone triggered IL1β secretion via non-canonical, caspase 8-dependent activation of the inflammasome. We treated 2 IL10R-deficient patients with severe and treatment-refractory infant-onset inflammatory bowel disease with the IL1-receptor antagonist anakinra. Both patients had marked clinical, endoscopic, and histologic responses after 4-7 weeks. This treatment served as successful bridge to allogeneic hematopoietic stem cell transplantation in 1 patient. Our findings indicate that loss of IL10 signaling leads to intestinal inflammation, at least in part, through increased production of IL1 by innate immune cells, leading to activation of CD4+ T cells. Agents that block IL1 signaling might be used to treat patients with inflammatory bowel disease resulting from IL10R deficiency.

IL‐10 Deficiency Blocks the Ability of LPS to Regulate Expression of Tolerance‐related Molecules on Dendritic Cells

Ability of LPS to regulate expression of tolerance-related molecules on dendritic cells is blocked by IL-10 deficiency (48.18)

Decreased Lamina Propria Effector Cell Responsiveness to Interleukin-10 in Ileal Crohn's Disease.

MicroRNA-10a Negatively Regulates CD4+ T Cell IL-10 Production Through Suppression of Blimp1.

IL-10 Modulates DSS-induced Colitis Through a Macrophage–ros–no Axis

IL-10 engages macrophages to shift Th17 cytokine dependency and pathogenicity during T-cell-mediated colitis

IL-10 Engages Macrophages to Shift Th17 Cytokine Dependency and Pathogenicity During T Cell-Mediated Colitis (MUC8P.729)

CD40 signaling augments IL-10 expression and the tolerogenicity of IL-10-induced regulatory dendritic cells

Interleukin 1β Mediates Intestinal Inflammation in Mice and Patients With Interleukin 10 Receptor Deficiency

Interleukin-10 regulates functions of dendritic cell through autophagy inhibition

Lipopolysaccharide Attenuates CD40 Ligand-Induced Regulatory B10 Cell Expansion and IL-10 Production in Mouse Splenocytes

Interleukin-10 From Marginal Zone Precursor B-Cell Subset Is Required for Costimulatory Blockade-Induced Transplantation Tolerance

A Regulatory Role for IL-10 Receptor Signaling in Development and B Cell Help of T Follicular Helper Cells in Mice

The absence of interleukin 10 affects the morphology, differentiation, granule content and the production of cryptidin-4 in Paneth cells in mice

Integrin CD11b Negatively Regulates TLR9-triggered Dendritic Cell Cross-Priming by Upregulating Microrna-146A.

IL-10 regulates murine lupus.

Deletion of IL-6 Exacerbates Colitis and Induces Systemic Inflammation in IL-10-Deficient Mice.

Tumor Necrosis Factor Suppresses Interleukin 10 in Peripheral B Cells Via Upregulating Bcl2-like Protein 12 in Patients with Inflammatory Bowel Disease.

IL-10 inhibits cytokine production by activated macrophages.

Mir-10A Inhibits Dendritic Cell Activation and Th1/Th17 Cell Immune Responses in IBD.